Low ADAMTS13 activity is associated with an increased risk of ischemic stroke

Michelle A H Sonneveld1, Moniek P M de Maat2, Marileen L P Portegies3

  • 1Department of Hematology, Department of Neurology, and.

Blood
|October 30, 2015
PubMed

Insights

Low ADAMTS13 activity increases ischemic stroke risk. Measuring ADAMTS13 activity improves stroke risk prediction beyond traditional factors.

Area of Science:

  • Cardiovascular Medicine
  • Hematology

Background:

  • ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin motif repeats 13) cleaves von Willebrand factor (VWF), reducing its activity and possessing antithrombotic properties.
  • Understanding the role of ADAMTS13 in cerebrovascular diseases like ischemic stroke is crucial for risk stratification.

Purpose of the Study:

  • To prospectively investigate the association between ADAMTS13 activity and the risk of incident ischemic stroke.
  • To evaluate the added value of ADAMTS13 activity in predicting ischemic stroke risk compared to established cardiovascular risk factors.

Main Methods:

  • A prospective population-based cohort study (Rotterdam Study) including 5941 individuals aged ≥55 years without prior stroke or TIA.
  • ADAMTS13 activity and VWF antigen (VWF:Ag) levels were measured at baseline.
  • Cox proportional hazard analysis and reclassification metrics (C-statistic, NRI) were used to assess associations and predictive value over a median follow-up of 10.7 years.

Main Results:

  • Individuals in the lowest quartile of ADAMTS13 activity had a significantly higher risk of ischemic stroke (HR, 1.65; 95% CI, 1.16-2.32) compared to the highest quartile, after adjusting for cardiovascular risk factors.
  • Incorporating ADAMTS13 activity into risk prediction models significantly improved stroke prediction accuracy, evidenced by an increase in the C-statistic and NRI.

Conclusions:

  • Low ADAMTS13 activity is an independent risk factor associated with an increased risk of ischemic stroke.
  • Assessing ADAMTS13 activity can enhance the prediction of ischemic stroke risk beyond traditional risk factors, potentially aiding in primary prevention strategies.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
582
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
426
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
750